From Yahoo Finance: 2025-06-11 08:58:00

Denmark’s Novo Nordisk partners with Deep Apple Therapeutics in an $812 million deal to develop drugs for cardiometabolic diseases, including obesity. Deep Apple’s AI platform screens billions of compounds to speed up drug discovery. Novo gains exclusive rights to develop non-incretin oral therapies, expanding its weight-loss drug market presence.

Novo aims to strengthen its position in the $150 billion weight-loss drug market. Recent partnerships and acquisitions, including deals with Lexicon Pharmaceuticals and United Laboratories International, show a commitment to developing next-generation treatments. The company ousted its CEO in May amid concerns about losing market share to competitors like Eli Lilly.

Deep Apple stands to receive up to $812 million in payments and potential royalties as part of its collaboration with Novo. The deal aims to drive innovation in the weight-loss drug market and improve Novo’s pipeline of new drugs. This partnership represents a strategic move for both companies in the highly competitive pharmaceutical industry.

Read more: Novo signs $812 million weight-loss drug license deal with US biotech Deep Apple